A New Paradigm in Thermocoagulation: Introducing the SEEG-Tx® System

Transforming Epilepsy Care with SEEG-Tx®. DIXI medical is proud to announce the regulatory submission of SEEG-Tx® , our first proprietary thermocoagulation system, to the U.S. Food and Drug Administration (FDA). This milestone marks a significant leap forward in delivering next-generation technology to clinicians managing drug-resistant epilepsy. Precision Through Innovation. The SEEG-Tx® system is engineered to deliver highly consistent bipolar ablation volumes. By utilizing dynamic, real-time power control, the system ensures stable energy delivery throughout the procedure, addressing a critical need for precision in neurosurgical interventions. Key Features for Clinicians:. Closed-Loop Automation: Supports controlled and reproducible ablations for improved procedural outcomes. Seamless Workflow Integration: Fully compatible with existing SEEG architectures, allowing for an intuitive transition from mapping to treatment., Enhanced Safety & Stability: Built on decades of clinical expertise and rigorous laboratory validation to ensure maximum reliability., Ergonomic Design: Features an intuitive interface designed hand-in-hand with leading neurosurgeons and neurologists. A Clinical Reality. “SEEG-Tx® was built in collaboration with clinicians who challenged us to rethink thermocoagulation,” says John Gale, Chief Scientific Officer. This system is the culmination of intensive R&D efforts aimed at making SEEG-guided thermocoagulation more efficient, controlled, and accessible. As the FDA review progresses, DIXI medical remains committed to pioneering solutions that empower medical teams and improve the lives of patients worldwide.